WO2011058478A1 - Triazolopyrimidines substituées comme inhibiteurs de pde8 - Google Patents

Triazolopyrimidines substituées comme inhibiteurs de pde8 Download PDF

Info

Publication number
WO2011058478A1
WO2011058478A1 PCT/IB2010/054953 IB2010054953W WO2011058478A1 WO 2011058478 A1 WO2011058478 A1 WO 2011058478A1 IB 2010054953 W IB2010054953 W IB 2010054953W WO 2011058478 A1 WO2011058478 A1 WO 2011058478A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
pyrimidin
amine
triazolo
morpholin
Prior art date
Application number
PCT/IB2010/054953
Other languages
English (en)
Inventor
Michelle Marie Claffey
Michael Paul Deninno
Robin Jean Kleiman
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of WO2011058478A1 publication Critical patent/WO2011058478A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • the present invention relates to the treatment of spinal cord injury, cognitive deficits associated with schizophrenia and/or Alzheimer's disease, and other neurodegenerative and/or neurological disorders in mammals, including humans. More particularly, this invention relates to substituted triazolopyrimidine inhibitors of the PDE8 enzyme, useful for the treatment of such disorders.
  • Adenosine and guanosine 3',5'-cyclic monophosphates are the second messengers that mediate the response of cells to a wide variety of hormones and neurotransmitters and modulate many metabolic processes.
  • Phosphodiesterases are the sole enzymes hydrolyzing these cyclic nucleotides and thus play pivotal roles in the physiological processes involving the nucleotide signaling pathway.
  • Phosphodiesterase-8 PDE8 is a family of cAMP-specific enzymes and plays an important role in many biological processes, including T-cell activation, testosterone production, adrenocortical hyperplasia, and thyroid function. See Wang et al., Biochemistry, 2008, 47 (48), 12760-8.
  • the present invention is directed to compounds of Formula I:
  • R is alkyl, haloalkyi, cycloalkyl, heterocycloalkyl, aminoalkyl, aryloxyalkyl, hydroxyalkyl, or alkoxyalkyl, wherein R may be optionally substituted with one or more substituents independently selected from halo, haloalkyi, alkyl, cycloalkyl, hydroxy, amino, and alkoxy;
  • R 2 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, wherein R 2 may be optionally substituted with one or more substituents independently selected from halo, haloalkyi, alkyl, cycloalkyl, hydroxy, amino, and alkoxy;
  • R 3 and R 4 are independently hydrogen, alkyl, or haloalkyi; and R 5 is a bond, methylene, or ethylene, wherein said methylene or ethylene may be substituted by a methyl or ethyl substituent;
  • This invention also includes pharmaceutically acceptable salts, prodrugs, hydrates, solvates, isomers, crystalline and non-crystalline forms, isomorphs, polymorphs, and metabolites of compounds of Formula I.
  • This invention also includes all tautomers and stereochemical isomers of these compounds.
  • This invention also is directed, in part, to a method for treating a PDE8 mediated disorder in a mammal.
  • Such disorders include spinal cord injury, cognitive deficits associated with schizophrenia and/or Alzheimer's disease, and other neurodegenerative and/or neurological disorders.
  • the method comprises administering a compound of Formula I or a pharmaceutically acceptable salt thereof, to the mammal in an amount that is therapeutically effective to treat the condition.
  • One embodiment of the present invention is a compound of Formula I as described above.
  • Another embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R 5 is -(CH 2 ) n -, wherein n is 0, 1 , or 2.
  • Another embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen, methyl, phenyl, oxazolyl, triazolyl, pyrazinyl, pyridazinyl, thiazolyl, pyrazolyl, imidazolyl, pyrimidinyl, or pyridinyl, wherein said methyl, phenyl, oxazolyl, triazolyl, pyrazinyl, pyridazinyl, thiazolyl, pyrazolyl, imidazolyl, pyrimidinyl, or pyridinyl may be optionally substituted with one or two substituents independently selected from halo, haloalkyl, alkyl, cycloalkyl, hydroxy, amino, and alkoxy.
  • Another embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen, methyl, phenyl, oxazolyl, triazolyl, pyrazinyl, pyridazinyl, thiazolyl, pyrazolyl, imidazolyl, pyrimidinyl, or pyridinyl, wherein said methyl, phenyl, oxazolyl, triazolyl, pyrazinyl, pyridazinyl, thiazolyl, pyrazolyl, imidazolyl, pyrimidinyl, or pyridinyl may be optionally substituted with one or two substituents independently selected from halo, haloalkyl, alkyl, cycloalkyl, hydroxy, amino, and alkoxy; and R 4 is hydrogen; provided that when R 2 is oxazolyl, triazolyl, pyrazinyl, thiazolyl
  • R is alkyl, haloalkyi, or cycloalkyl
  • R 2 is hydrogen, phenyl, oxazolyl, thiazolyl, pyrazolyl, imidazolyl, pyrimidinyl, or pyridinyl, wherein said phenyl, oxazolyl, thiazolyl, pyrazolyl, imidazolyl, pyrimidinyl, or pyridinyl may be optionally substituted with one or two substituents independently selected from halo, haloalkyi, and alkyl; and R 3 and R 4 are hydrogen.
  • Another embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen, phenyl, oxazolyl, or thiazolyl, wherein said phenyl may be optionally substituted with one or two substituents independently selected from halo, haloalkyi, and alkyl, and wherein said oxazolyl or thiazolyl may be optionally substituted with one or two substituents independently selected from haloalkyi and alkyl.
  • Another embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R is methyl, trifluoromethyl, or cyclopropyl; and R 2 is hydrogen, phenyl, oxazolyl, thiazolyl, pyrazolyl, imidazolyl, pyrimidinyl, or pyridinyl, wherein said phenyl, oxazolyl, thiazolyl, pyrazolyl, imidazolyl, pyrimidinyl, or pyridinyl may be optionally substituted with one or two substituents independently selected from fluoro, trifluoromethyl, and methyl.
  • Another embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein R is methyl, cyclopropyl, or trifluoromethyl; R 2 is hydrogen, phenyl, oxazolyl, or thiazolyl, wherein said phenyl, oxazolyl, or thiazolyl may be optionally substituted with one or two substituents independently selected from ethyl, methyl, and trifluoromethyl; and R 3 and R 4 are hydrogen.
  • Another embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein n is 1 ; R is methyl, cyclopropyl, or trifluoromethyl; R 2 is hydrogen, phenyl, oxazolyl, or thiazolyl, wherein said phenyl, oxazolyl, or thiazolyl may be optionally substituted with one or two methyl substituents; and R 3 and R 4 are hydrogen.
  • Another embodiment of the present invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, selected from:
  • Another embodiment of the present invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • neurodegenerative disease or disorder the method comprising administering a compound of Formula I, or a pharmaceutically acceptable salt thereof.
  • neurodegenerative disease or disorder the method comprising administering a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the neurodegenerative disease or disorder is Alzheimer's disease, Parkinson's disease, multiple sclerosis, stroke, spinal cord injury, amyotrophic lateral sclerosis, traumatic brain injury, Huntington's disease, cognitive impairment associated with Alzheimer's disease, age-related cognitive decline, schizophrenia, or ADHD.
  • the neurodegenerative disease or disorder is Alzheimer's disease, Parkinson's disease, multiple sclerosis, stroke, spinal cord injury, amyotrophic lateral sclerosis, traumatic brain injury, Huntington's disease, cognitive impairment associated with Alzheimer's disease, age-related cognitive decline, schizophrenia, or ADHD.
  • neurodegenerative disease or disorder the method comprising administering a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the neurodegenerative disease or disorder is spinal cord injury.
  • R is alkyl, haloalkyl, or cycloalkyi
  • R 2 is hydrogen, phenyl, oxazolyl, thiazolyl, pyrazolyl, imidazolyl, pyrimidinyl, or pyridinyl, wherein said phenyl, oxazolyl, thiazolyl, pyrazolyl, imidazolyl, pyrimidinyl, or pyridinyl may be optionally substituted with one or two substituents independently selected from halo, haloalkyl, and alkyl; and R 3 is hydrogen.
  • R is methyl, trifluoromethyl, or cyclopropyl
  • R 2 is hydrogen, phenyl, oxazolyl, thiazolyl, pyrazolyl, imidazolyl, pyrimidinyl, or pyridinyl, wherein said phenyl, oxazolyl, thiazolyl, pyrazolyl, imidazolyl, pyrimidinyl, or pyridinyl may be optionally substituted with one or two substituents independently selected from fluoro, trifluoromethyl, and methyl; and R 3 is hydrogen.
  • alkyl refers to a linear or branched-chain saturated hydrocarbyl substituent (i.e., a substituent obtained from a hydrocarbon by removal of a hydrogen) containing from one to twenty carbon atoms; in one embodiment from one to twelve carbon atoms; in another embodiment, from one to ten carbon atoms; in another embodiment, from one to six carbon atoms; and in another embodiment, from one to four carbon atoms.
  • substituents include methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n- butyl, isobutyl, sec-butyl and ieri-butyl), pentyl, isoamyl, hexyl and the like.
  • cycloalkyi refers to a carbocyclic substituent obtained by removing a hydrogen from a saturated carbocyclic molecule and having three to fourteen carbon atoms. In one embodiment, a cycloalkyi substituent has three to ten carbon atoms. Examples of cycloalkyi include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • cycloalkyi also includes substituents that are fused to a C 6 -Ci 0 aromatic ring or to a 5-10-membered heteroaromatic ring, wherein a group having such a fused cycloalkyi group as a substituent is bound to a carbon atom of the cycloalkyi group.
  • a fused cycloalkyi group is substituted with one or more substituents, the one or more substituents, unless otherwise specified, are each bound to a carbon atom of the cycloalkyi group.
  • a cycloalkyi may be a single ring, which typically contains from 3 to 6 ring atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Alternatively, 2 or 3 rings may be fused together, such as bicyclodecanyl and decalinyl.
  • aryl refers to an aromatic substituent containing one ring or two or three fused rings. The aryl substituent may have six to eighteen carbon atoms. As an example, the aryl substituent may have six to fourteen carbon atoms.
  • aryl may refer to
  • aryl also includes substituents such as phenyl, naphthyl and anthracenyl that are fused to a C 4 -Ci 0 carbocyclic ring, such as a C 5 - or a C 6 -carbocyclic ring, or to a 4-10-membered heterocyclic ring, wherein a group having such a fused aryl group as a substituent is bound to an aromatic carbon of the aryl group.
  • fused aryl group When such a fused aryl group is substituted with one or more substituents, the one or more substituents, unless otherwise specified, are each bound to an aromatic carbon of the fused aryl group.
  • aryl groups include accordingly phenyl, naphthalenyl, tetrahydronaphthalenyl (also known as “tetralinyl”), indenyl, isoindenyl, indanyl, anthracenyl, phenanthrenyl, and benzonaphthenyl (also known as “phenalenyl”).
  • the number of carbon atoms in a hydrocarbyl substituent is indicated by the prefix “C x -C y " or "C x-y ,” wherein x is the minimum and y is the maximum number of carbon atoms in the substituent.
  • C x -C y or "C x-y ,” wherein x is the minimum and y is the maximum number of carbon atoms in the substituent.
  • Ci-C 6 alkyl and “Ci_ 6 alkyl” both refer to an alkyl substituent containing from 1 to 6 carbon atoms.
  • C 3 -C 6 cycloalkyl and C 3 . 6 cycloalkyl refer to saturated cycloalkyl containing from 3 to 6 carbon ring atoms.
  • the number of atoms in a cyclic substituent containing one or more heteroatoms is indicated by the prefix "X-Y-membered", wherein x is the minimum and y is the maximum number of atoms forming the cyclic moiety of the substituent.
  • X-Y-membered the prefix "X-Y-membered”
  • x the minimum
  • y the maximum number of atoms forming the cyclic moiety of the substituent.
  • 5-8-membered heterocycloalkyi refers to a heterocycloalkyi containing from 5 to 8 atoms, including one or more heteroatoms, in the cyclic moiety of the heterocycloalkyi.
  • hydroxy refers to -OH.
  • prefix indicates that the substituent to which the prefix is attached is substituted with one or more hydroxy substituents.
  • Compounds bearing a carbon to which one or more hydroxy substituents are attached include, for example, alcohols, enols and phenol.
  • hydroxyalkyl refers to an alkyl that is substituted with at least one hydroxy substituent.
  • examples of hydroxyalkyl include hydroxymethyl, hydroxyethyl, hydroxypropyl and hydroxybutyl.
  • cyano (also referred to as “nitrile”) means CN.
  • amino refers to NH 2 .
  • alkylamino refers to an amino group, wherein at least one alkyl chain is bonded to the amino nitrogen in place of a hydrogen atom.
  • alkylamino substituents include monoalkylamino such as methylamino (exemplified by the formula NH(CH 3 )), and dialkylamino such as dimethylamino (exemplified by the formula -N(CH 3 ) 2 ).
  • halogen refers to fluorine (which may be depicted as F), chlorine (which may be depicted as CI), bromine (which may be depicted as Br), or iodine (which may be depicted as I).
  • the halogen is chlorine.
  • the halogen is fluorine.
  • the halogen is bromine.
  • halo indicates that the substituent to which the prefix is attached is substituted with one or more independently selected halogen substituents.
  • haloalkyl refers to an alkyl that is substituted with at least one halogen substituent. Where more than one hydrogen is replaced with halogens, the halogens may be identical or different.
  • haloalkyls examples include chloromethyl, dichloromethyl, difluorochloromethyl,
  • haloalkoxy refers to an alkoxy that is substituted with at least one halogen substituent. Examples of haloalkoxy substituents include chloromethoxy, 1 - bromoethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy (also known as
  • alkoxy refers to an alkyl linked to an oxygen, which may also be represented as -OR, wherein the R represents the alkyl group. Examples of alkoxy include methoxy, ethoxy, propoxy and butoxy.
  • heterocycloalkyl refers to a substituent obtained by removing a hydrogen from a saturated or partially saturated ring structure containing a total of 4 to 14 ring atoms. At least one of the ring atoms is a heteroatom usually selected from oxygen, nitrogen, or sulfur.
  • a heterocycloalkyl alternatively may comprise 2 or 3 rings fused together, wherein at least one such ring contains a heteroatom as a ring atom (i.e., nitrogen, oxygen, or sulfur).
  • the ring atom of the heterocycloalkyl substituent that is bound to the group may be the at least one heteroatom, or it may be a ring carbon atom, where the ring carbon atom may be in the same ring as the at least one heteroatom or where the ring carbon atom may be in a different ring from the at least one heteroatom.
  • the group or substituent may be bound to the at least one heteroatom, or it may be bound to a ring carbon atom, where the ring carbon atom may be in the same ring as the at least one heteroatom or where the ring carbon atom may be in a different ring from the at least one heteroatom.
  • heterocycloalkyi also includes substituents that are fused to a C6-C 10 aromatic ring or to a 5-10-membered heteroaromatic ring, wherein a group having such a fused heterocycloalkyi group as a substituent is bound to a heteroatom of the heterocyclocalkyi group or to a carbon atom of the heterocycloalkyi group.
  • a fused heterocycloalkyi group is substituted with one or more substituents, the one or more substituents, unless otherwise specified, are each bound to a heteroatom of the heterocyclocalkyi group or to a carbon atom of the heterocycloalkyi group.
  • heteroaryl refers to an aromatic ring structure containing from 5 to 14 ring atoms in which at least one of the ring atoms is a heteroatom (i.e., oxygen, nitrogen, or sulfur), with the remaining ring atoms being independently selected from the group consisting of carbon, oxygen, nitrogen, and sulfur.
  • a heteroaryl may be a single ring or 2 or 3 fused rings.
  • heteroaryl substituents include: 6-membered ring substituents such as pyridyl, pyrazyl, pyrimidinyl, and pyridazinyl; 5-membered ring substituents such as triazolyl, imidazolyl, furanyl, thiophenyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, 1 ,2,3-, 1 ,2,4-, 1 ,2,5-, or 1 ,3,4-oxadiazolyl and isothiazolyl; 6-/5-membered fused ring substituents such as benzothiofuranyl,
  • the ring atom of the heteroaryl substituent that is bound to the group may be the at least one heteroatom, or it may be a ring carbon atom, where the ring carbon atom may be in the same ring as the at least one heteroatom or where the ring carbon atom may be in a different ring from the at least one heteroatom.
  • heteroaryl also includes pyridyl /V-oxides and groups containing a pyridine /V-oxide ring. Examples of single ring heteroaryls include furanyl, thiophenyl (also known as
  • thiofuranyl pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl [including 1 ,2,4-oxadiazolyl (also known as “azoximyl”), 1 ,2,5-oxadiazolyl (also known as “furazanyl”), or 1 ,3,4-oxadiazolyl], pyridinyl (also known as "azinyl”), diazinyl [including pyridazinyl (also known as “1 ,2-diazinyl”), pyrimidinyl (also known as “1 ,3-diazinyl” or “pyrimidyl”), or pyrazinyl (also known as "1 ,4-diazinyl”)], and triaziny
  • 2-fused-ring heteroaryls examples include indolizinyl, pyrindinyl, purinyl,
  • naphthyridinyl pyridopyridinyl (including pyrido[3,4-£>]-pyridinyl, pyrido[3,2-£>]pyridinyl, or pyrido[4,3-j ]pyridinyl), and pteridinyl, indolyl, isoindolyl, isoindazolyl, phthalazinyl, quinoxalinyl, quinazolinyl, benzoxazolyl, indoxazinyl, anthranilyl, benzoxadiazolyl, benzofuranyl,
  • 3-fused-ring heteroaryls or heterocycloalkyls include 5,6-dihydro-4/-/- imidazo[4,5,1-/y]quinoline, 4,5-dihydroimidazo[4,5,1-ft/]indole, 4,5,6J-tetrahydroimidazo[4,5,1- y ' /c][1]benzazepine, and dibenzofuranyl.
  • fused ring heteroaryls include benzo-fused heteroaryls such as indolyl, isoindolyl (also known as “isobenzazolyl” or “pseudoisoindolyl”), benzazinyl [including quinolinyl (also known as “1 -benzazinyl”) or isoquinolinyl (also known as “2-benzazinyl”)], phthalazinyl, quinoxalinyl, quinazolinyl, benzodiazinyl [including cinnolinyl (also known as “1 ,2- benzodiazinyl”) or quinazolinyl (also known as “1 ,3-benzodiazinyl”)], benzoxazolyl, indoxazinyl (also known as “benzisoxazolyl”), benzoxadiazolyl, benzofuranyl (also known as “coumaronyl”), isobenzofuranyl, benzothieny
  • benzothiofuranyl isobenzothienyl (also known as “isobenzothiophenyl,” “isothianaphthenyl,” or “isobenzothiofuranyl”), benzothiazolyl, benzothiadiazolyl, benzimidazolyl, benzotriazolyl, benzoxazinyl, benzisoxazinyl (including 1 ,2-benzisoxazinyl or 1 ,4-benzisoxazinyl), carbazolyl, and acridinyl.
  • heteroaryl also includes substituents such as pyridyl and quinolinyl that are fused to a C 4 -Ci 0 carbocyclic ring, such as a C 5 or a C 6 carbocyclic ring, or to a 4-10-membered heterocyclic ring, wherein a group having such a fused aryl group as a substituent is bound to an aromatic carbon of the heteroaryl group or to a heteroatom of the heteroaryl group.
  • the one or more substituents are each bound to an aromatic carbon of the heteroaryl group or to a heteroatom of the heteroaryl group.
  • heteroaryls and heterocycloalkyls include: 3-1/-/-benzimidazol-2- one, (1-substituted)-2-oxo-benzimidazol-3-yl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2- tetrahydropyranyl, 3-tetrahydropyranyl, 4-tetrahydropyranyl, [1 ,3]-dioxalanyl, [1 ,3]-dithiolanyl, [1 ,3]-dioxanyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 2-morpholinyl, 3-morpholinyl, 4- morpholinyl, 2-thiomorpholinyl, 3-thiomorpholinyl, 4-thiomorpholinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-piperazinyl, 2-piperazinyl, 2-pipe
  • a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached).
  • a group derived from imidazole may be imidazol-1-yl (N-attached) or imidazol-2-yl (C-attached).
  • a non-hydrogen substituent is in the place of a hydrogen attached to a carbon or nitrogen of the substituent.
  • a substituted alkyl substituent is an alkyl substituent wherein at least one non-hydrogen substituent is in the place of a hydrogen substituent on the alkyl substituent.
  • monofluoroalkyl is alkyl substituted with a fluoro substituent
  • difluoroalkyl is alkyl substituted with two fluoro substituents. It should be recognized that if there is more than one substitution on a substituent, each non-hydrogen substituent may be identical or different (unless otherwise stated).
  • substituent may be either substituted or not substituted. If a carbon of a substituent is described as being optionally substituted with one or more of a list of substituents, one or more of the hydrogens on the carbon (to the extent there are any) may separately and/or together be replaced with an independently selected optional substituent. If a nitrogen of a substituent is described as being optionally substituted with one or more of a list of substituents, one or more of the hydrogens on the nitrogen (to the extent there are any) may each be replaced with an independently selected optional substituent.
  • One exemplary substituent may be depicted as -NR'R", wherein R' and R" together with the nitrogen atom to which they are attached, may form a heterocyclic ring.
  • the heterocyclic ring formed from R' and R" together with the nitrogen atom to which they are attached may be partially or fully saturated.
  • the heterocyclic ring consists of 4 to 7 atoms.
  • the heterocyclic ring is selected from the group consisting of pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, and thiazolyl.
  • substituents are collectively described as being optionally substituted by one or more of a list of substituents, the group may include: (1 ) unsubstitutable substituents, (2) substitutable substituents that are not substituted by the optional substituents, and/or (3) substitutable substituents that are substituted by one or more of the optional substituents.
  • a substituent is described as being optionally substituted with up to a particular number of non-hydrogen substituents, that substituent may be either (1 ) not substituted; or (2) substituted by up to that particular number of non-hydrogen substituents or by up to the maximum number of substitutable positions on the substituent, whichever is less.
  • a substituent is described as a heteroaryl optionally substituted with up to 3 non- hydrogen substituents, then any heteroaryl with less than 3 substitutable positions would be optionally substituted by up to only as many non-hydrogen substituents as the heteroaryl has substitutable positions.
  • tetrazolyl which has only one substitutable position
  • an amino nitrogen is described as being optionally substituted with up to 2 non-hydrogen substituents, then the nitrogen will be optionally substituted with up to 2 non-hydrogen substituents if the amino nitrogen is a primary nitrogen, whereas the amino nitrogen will be optionally substituted with up to only 1 non-hydrogen substituent if the amino nitrogen is a secondary nitrogen.
  • alkylcycloalkyl contains two moieties: alkyl and cycloalkyl.
  • a C C 6 prefix on Ci-C 6 alkylcycloalkyl means that the alkyl moiety of the alkylcycloalkyl contains from 1 to 6 carbon atoms; the Ci-C 6 prefix does not describe the cycloalkyi moiety.
  • the prefix "halo" on haloalkoxyalkyl indicates that only the alkoxy moiety of the alkoxyalkyl substituent is substituted with one or more halogen substituents.
  • each substituent is selected independent of the other. Each substituent therefore may be identical to or different from the other substituent(s).
  • Form I may be hereinafter referred to as a "compound(s) of the invention.” Such terms are also defined to include all forms of the compound of Formula I, including hydrates, solvates, isomers, crystalline and non-crystalline forms, isomorphs, polymorphs, and metabolites thereof.
  • CDCI 3 Deuterated chloroform
  • the compound may exist in the form of optical isomers (enantiomers).
  • the present invention comprises enantiomers and mixtures, including racemic mixtures of the compounds of Formula I.
  • the present invention comprises diastereomeric forms (individual diastereomers and mixtures thereof) of compounds.
  • geometric isomers may arise.
  • the present invention comprises the tautomeric forms of compounds of Formula I.
  • tautomeric isomerism 'tautomerism'
  • This can take the form of proton tautomerism in compounds of Formula I containing, for example, an imino, keto, or oxime group, or so-called valence tautomerism in compounds which contain an aromatic moiety. It follows that a single compound may exhibit more than one type of isomerism.
  • the various ratios of the tautomers in solid and liquid form are dependent on the various substituents on the molecule as well as the particular crystallization technique used to isolate a compound.
  • the compounds of this invention may be used in the form of salts derived from inorganic or organic acids.
  • a salt of the compound may be advantageous due to one or more of the salt's physical properties, such as enhanced pharmaceutical stability in differing temperatures and humidities, or a desirable solubility in water or oil.
  • a salt of a compound also may be used as an aid in the isolation, purification, and/or resolution of the compound.
  • the salt preferably is pharmaceutically acceptable.
  • pharmaceutically acceptable salt refers to a salt prepared by combining a compound of Formula I with an acid whose anion, or a base whose cation, is generally considered suitable for human consumption.
  • Pharmaceutically acceptable salts are particularly useful as products of the methods of the present invention because of their greater aqueous solubility relative to the parent compound.
  • salts of the compounds of this invention are nontoxic "pharmaceutically acceptable salts.”
  • Salts encompassed within the term “pharmaceutically acceptable salts” refer to non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid.
  • Suitable pharmaceutically acceptable acid addition salts of the compounds of the present invention when possible include those derived from inorganic acids, such as hydrochloric, hydrobromic, hydrofluoric, boric, fluoroboric, phosphoric, metaphosphoric, nitric, carbonic, sulfonic, and sulfuric acids, and organic acids such as acetic, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isothionic, lactic, lactobionic, maleic, malic, methanesulfonic, trifluoromethanesulfonic, succinic, toluenesulfonic, tartaric, and trifluoroacetic acids.
  • Suitable organic acids generally include, for example, aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids.
  • suitable organic acids include acetate, trifluoroacetate, formate, propionate, succinate, glycolate, gluconate, digluconate, lactate, malate, tartaric acid, citrate, ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate, glutamate, benzoate, anthranilic acid, stearate, salicylate, p-hydroxybenzoate, phenylacetate, mandelate, embonate (pamoate), methanesulfonate, ethanesulfonate, benzenesulfonate, pantothenate,
  • toluenesulfonate 2-hydroxyethanesulfonate, sulfanilate, cyclohexylaminosulfonate, algenic acid, ⁇ -hydroxybutyric acid, galactarate, galacturonate, adipate, alginate, butyrate, camphorate, camphorsulfonate, cyclopentanepropionate, dodecylsulfate, glycoheptanoate,
  • glycerophosphate heptanoate, hexanoate, nicotinate, 2-naphthalesulfonate, oxalate, palmoate, pectinate, 3-phenylpropionate, picrate, pivalate, thiocyanate, and undecanoate.
  • suitable pharmaceutically acceptable salts thereof may include alkali metal salts, i.e., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts.
  • base salts are formed from bases which form non-toxic salts, including aluminum, arginine, benzathine, choline, diethylamine, diethanolamine, glycine, lysine, meglumine, ethanolamine, tromethamine and zinc salts.
  • Organic salts may be made from secondary, tertiary or quaternary amine salts, such as tromethamine, diethylamine, ⁇ /, ⁇ /'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (/V-methylglucamine), and procaine.
  • secondary, tertiary or quaternary amine salts such as tromethamine, diethylamine, ⁇ /, ⁇ /'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (/V-methylglucamine), and procaine.
  • Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl (Ci-C 6 ) halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (i.e., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (i.e., decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides), arylalkyl halides (i.e., benzyl and phenethyl bromides), and others.
  • agents such as lower alkyl (Ci-C 6 ) halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (i.e.,
  • hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.
  • the present invention also includes isotopically labeled compounds, which are identical to those recited in Formula I, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chlorine, such as 2 H, 3 H, 3 C, C, 4 C, 5 N, 8 0, 7 0, 3 P, 32 P, 35 S, 8 F, and 36 CI, respectively.
  • Isotopically labeled compounds of Formula I of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Preparations below, by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
  • the invention also relates to prodrugs of the compounds of Formula I.
  • Certain derivatives of compounds of Formula I which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into compounds of Formula I having the desired activity, for example, by hydrolytic cleavage.
  • Such derivatives are referred to as "prodrugs”. Further information on the use of prodrugs may be found in Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series, 1975 (T. Higuchi and W. Stella) and Bioreversible Carriers in Drug Design, Pergamon Press, 1987 (Ed. E. B. Roche, American Pharmaceutical Association).
  • Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of Formula I with certain moieties known to those skilled in the art as 'pro-moieties' as described, for example, in Design of Prodrugs by H. Bundgaard (Elsevier, 1985).
  • prodrugs in accordance with the invention include:
  • the compound of Formula I contains a primary or secondary amino functionality, or an amide which is functionalized into a suitably metabolically labile group, e.g., a hydrolyzable group (amide, carbamate, urea, phosphonate, sulfonate, etc.) on the compound of Formula I .
  • a suitably metabolically labile group e.g., a hydrolyzable group (amide, carbamate, urea, phosphonate, sulfonate, etc.) on the compound of Formula I .
  • a compound of the invention is administered in an amount effective to treat a condition as described herein.
  • the compounds of the invention are administered by any suitable route in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.
  • Therapeutically effective doses of the compounds required to treat the progress of the medical condition are readily ascertained by one of ordinary skill in the art using preclinical and clinical approaches familiar to the medicinal arts.
  • the compounds of the invention may be administered orally.
  • Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth.
  • the compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ.
  • suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intra urethra I, intrasternal, intracranial, intramuscular and subcutaneous.
  • Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
  • the compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally.
  • the compounds of the invention can also be administered intranasally or by inhalation.
  • the compounds of the invention may be administered rectally or vaginally.
  • the compounds of the invention may also be administered directly to the eye or ear.
  • the dosage regimen for the compounds and/or compositions containing the compounds is based on a variety of factors, including the type, age, weight, sex and medical condition of the patient; the severity of the condition; the route of administration; and the activity of the particular compound employed. Thus the dosage regimen may vary widely. Dosage levels of the order from about 0.01 mg to about 100 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions. In one embodiment, the total daily dose of a compound of the invention (administered in single or divided doses) is typically from about 0.01 to about 100 mg/kg.
  • the total daily dose of the compound of the invention is from about 0.1 to about 50 mg/kg, and in another embodiment, from about 0.5 to about 30 mg/kg (i.e., mg compound of the invention per kg body weight). In one embodiment, dosing is from 0.01 to 10 mg/kg/day. In another embodiment, dosing is from 0.1 to 1.0 mg/kg/day. Dosage unit compositions may contain such amounts or submultiples thereof to make up the daily dose. In many instances, the administration of the compound will be repeated a plurality of times in a day (typically no greater than 4 times). Multiple doses per day typically may be used to increase the total daily dose, if desired.
  • compositions may be provided in the form of tablets containing 0.01 , 0.05, 0.1 , 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 75.0, 100, 125, 150, 175, 200, 250 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient.
  • a medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, or in another embodiment, from about 1 mg to about 100 mg of active ingredient.
  • doses may range from about 0.01 to about 10 mg/kg/min during a constant rate infusion.
  • Suitable subjects according to the present invention include mammalian subjects. Mammals according to the present invention include, but are not limited to, canine, feline, bovine, caprine, equine, ovine, porcine, rodents, lagomorphs, primates, and the like, and encompass mammals in utero. In one embodiment, humans are suitable subjects. Human subjects may be of either gender and at any stage of development.
  • the invention comprises the use of one or more compounds of the invention for the preparation of a medicament for the treatment of the conditions recited herein.
  • the compound of the invention can be administered as compound per se.
  • pharmaceutically acceptable salts are suitable for medical applications because of their greater aqueous solubility relative to the parent compound.
  • the present invention comprises pharmaceutical compositions.
  • Such pharmaceutical compositions comprise a compound of the invention presented with a pharmaceutically acceptable carrier.
  • the carrier can be a solid, a liquid, or both, and may be formulated with the compound as a unit-dose composition, for example, a tablet, which can contain from 0.05% to 95% by weight of the active compounds.
  • a compound of the invention may be coupled with suitable polymers as targetable drug carriers. Other pharmacologically active substances can also be present.
  • the compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.
  • the active compounds and compositions for example, may be administered orally, rectally, parenterally, or topically.
  • Oral administration of a solid dose form may be, for example, presented in discrete units, such as hard or soft capsules, pills, cachets, lozenges, or tablets, each containing a
  • the oral administration may be in a powder or granule form.
  • the oral dose form is sub-lingual, such as, for example, a lozenge.
  • the compounds of Formula I are ordinarily combined with one or more adjuvants.
  • Such capsules or tablets may contain a controlled-release formulation.
  • the dosage forms also may comprise buffering agents or may be prepared with enteric coatings.
  • oral administration may be in a liquid dose form.
  • Liquid dosage forms for oral administration include, for example, pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art
  • compositions also may comprise adjuvants, such as wetting, emulsifying, suspending, flavoring (e.g., sweetening), and/or perfuming agents.
  • adjuvants such as wetting, emulsifying, suspending, flavoring (e.g., sweetening), and/or perfuming agents.
  • the present invention comprises a parenteral dose form.
  • Parenter administration includes, for example, subcutaneous injections, intravenous injections, intraperitoneal injections, intramuscular injections, intrasternal injections, and infusion.
  • injectable preparations i.e., sterile injectable aqueous or oleaginous suspensions
  • suitable dispersing, wetting, and/or suspending agents may be formulated according to the known art using suitable dispersing, wetting, and/or suspending agents.
  • Topical administration includes, for example, transdermal administration, such as via transdermal patches or iontophoresis devices, intraocular administration, or intranasal or inhalation administration.
  • Compositions for topical administration also include, for example, topical gels, sprays, ointments, and creams.
  • a topical formulation may include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas.
  • Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions. Liposomes may also be used.
  • Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol.
  • Penetration enhancers may be incorporated; see, for example, Finnin and Morgan, J. Pharm. Sci. , 1999, 88, 955-958.
  • Formulations suitable for topical administration to the eye include, for example, eye drops wherein the compound of this invention is dissolved or suspended in a suitable carrier.
  • a typical formulation suitable for ocular or aural administration may be in the form of drops of a micronized suspension or solution in isotonic, pH-adjusted, sterile saline.
  • Other formulations suitable for ocular and aural administration include ointments, biodegradable (i.e., absorbable gel sponges, collagen) and non-biodegradable (i.e., silicone) implants, wafers, lenses and particulate or vesicular systems, such as niosomes or liposomes.
  • a polymer such as crossed-linked polyacrylic acid, polyvinyl alcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropylmethylcellulose, hydroxyethylcellulose, or methylcellulose, or a heteropolysaccharide polymer, for example, gelan gum, may be incorporated together with a preservative, such as benzalkonium chloride.
  • a preservative such as benzalkonium chloride.
  • Such formulations may also be delivered by iontophoresis.
  • the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant.
  • Formulations suitable for intranasal administration are typically administered in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray from a pressurized container, pump, spray, atomizer (preferably an atomizer using electrohydrodynamics to produce a fine mist), or nebulizer, with or without the use of a suitable propellant, such as 1 , 1 , 1 ,2-tetrafluoroethane or 1 ,1 ,1 ,2,3,3,3- heptafluoropropane.
  • a suitable propellant such as 1 , 1 , 1 ,2-tetrafluoroethane or 1 ,1 ,1 ,2,3,3,3- heptafluoropropane.
  • the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.
  • the present invention comprises a rectal dose form.
  • rectal dose form may be in the form of, for example, a suppository. Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.
  • compositions of the invention may be prepared by any of the well-known techniques of pharmacy, such as effective formulation and administration procedures.
  • effective formulations and administration procedures are well known in the art and are described in standard textbooks.
  • Formulation of drugs is discussed in, for example, Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania, 1975; Liberman ef a/., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Kibbe ef a/., Eds., Handbook of Pharmaceutical Excipients (3 rd Ed.), American Pharmaceutical Association, Washington, 1999.
  • the compounds of the present invention can be used, alone or in combination with other therapeutic agents, in the treatment of various conditions or disease states.
  • the compound(s) of the present invention and other therapeutic agent(s) may be may be administered
  • An exemplary therapeutic agent may be, for example, a metabotropic glutamate receptor agonist.
  • the administration of two or more compounds "in combination" means that the two compounds are administered closely enough in time that the presence of one alters the biological effects of the other.
  • the two or more compounds may be administered
  • simultaneous administration may be carried out by mixing the compounds prior to administration or by administering the compounds at the same point in time but at different anatomic sites or using different routes of
  • administering and “administered simultaneously” mean that the compounds are administered in combination.
  • kits that are suitable for use in performing the methods of treatment described above.
  • the kit contains a first dosage form comprising one or more of the compounds of the present invention and a container for the dosage, in quantities sufficient to carry out the methods of the present invention.
  • the kit of the present invention comprises one or more compounds of the invention.
  • the invention relates to the novel intermediates useful for preparing the compounds of the invention.
  • the compounds of Formula I may be prepared by the methods described below, together with synthetic methods known in the art of organic chemistry, or modifications and derivatizations that are familiar to those of ordinary skill in the art.
  • the starting materials used herein are commercially available or may be prepared by routine methods known in the art
  • Preferred methods include, but are not limited to, those described below.
  • any of the following synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This can be achieved by means of conventional protecting groups, such as those described in T. W. Greene, Protective Groups in Organic Chemistry, John Wiley & Sons, 1981 ; T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1991 ; and T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1999, which are hereby incorporated by reference.
  • conventional protecting groups such as those described in T. W. Greene, Protective Groups in Organic Chemistry, John Wiley & Sons, 1981 ; T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1991 ; and T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley &
  • the compounds of Formula l(c) can be prepared as described in Scheme 1 starting from aminodichloropyrimidines II and amines III. Methods of preparing compounds II and compounds III are outlined later in Schemes 2 and 3. Compounds of Formula IV can be prepared from the corresponding aminodichloropyrimidine II by reacting with racemic or enantiomerically-enriched amines of the formula III.
  • Compounds II and III are combined in the presence of a base, such as diisopropylethylamine, triethylamine or sodium carbonate in a polar solvent such as N- methylpyrrolidinone at a temperature of about 50 °C to about 150 °C, preferably at about 125 °C for about 10 h to about 24 h, or in MeCN at a temperature of 80 °C for up to 36 h to yield compounds IV.
  • a base such as diisopropylethylamine, triethylamine or sodium carbonate
  • a polar solvent such as N- methylpyrrolidinone
  • triazolopyrimidines V are cyclized by treatment with a nitrosylating agent in acidic solution, to yield triazolopyrimidines V.
  • One method of triazole cyclization uses sodium nitrite in a solvent mixture of water, dichloromethane and acetic acid at a temperature of about 0 °C to about 30 °C, typically at ambient temperature for about 1 - 6 hours.
  • another method employs sodium nitrite in MeTHF with the addition of 1 N HCI at ambient temperature for about 1 hour.
  • the resulting chloropyrimidines V can then be reacted with a source of ammonia, such as ammonium hydroxide or anhydrous ammonia dissolved in organic solvents such as methanol, ethanol, THF, MeTHF or dioxane, at a temperature of about 40 °C to about 100 °C, preferably at about 75 °C for about 4 hours to 24 hours and typically in a sealed pressure vessel to provide compounds of formula l(a).
  • a source of ammonia such as ammonium hydroxide or anhydrous ammonia dissolved in organic solvents such as methanol, ethanol, THF, MeTHF or dioxane
  • Formula 1(a) compounds can be debenzylated to provide compounds of Formula 1(b).
  • the reduction is preferably carried out using a palladium catalyst, more preferably palladium hydroxide on carbon, and an acid catalyst, such as hydrochloric acid, sulfuric acid or acetic acid, in a solvent such as methanol, ethanol or MeTHF under between 1 and 4 atmospheres of hydrogen gas, preferably 3 atmospheres, at a temperature from ambient temperature to 50 °C, preferably at ambient temperature for about 2 hours to about 24 hours.
  • a compound of Formula l(b) wherein R is defined above is reacted with a heterocyclic halide in the presence of a base, preferably an amine base such as diisopropylethylamine in a polar solvent such as acetonitrile, 2-propanol or A/,A/-dimethylformamide at a temperature of 40 °C to the reflux temperature of the solvent, preferably at about 75 °C for about 1 -3 days.
  • a base preferably an amine base such as diisopropylethylamine
  • a polar solvent such as acetonitrile, 2-propanol or A/,A/-dimethylformamide
  • a compound of Formula l(b) wherein R is defined above is reacted with a heterocyclic halide in the presence of a palladium catalyst such as Pd 2 (dba) 3 , a phosphine ligand, such as xantphos, or X-Phos, and a base such as cesium carbonate, potassium hydroxide, or sodium ieri-butoxide, in a reaction-inert solvent such as dioxane, ieri-butanol, or ieri-amyl alcohol at a temperature of 50 °C to the boiling point of the solvent, preferably at about 100-1 10 °C for about one to about 24 hours.
  • a palladium catalyst such as Pd 2 (dba) 3
  • a phosphine ligand such as xantphos, or X-Phos
  • a base such as cesium carbonate, potassium hydroxide, or sodium ieri-butoxide
  • a reaction-inert solvent such as dioxan
  • the Formula l(b) compound and aldehyde are combined in a reaction-inert solvent such as dichloroethane, acetonitrile, THF, or MeTHF (or mixtures thereof), followed by the addition of a reducing agent, preferably sodium triacetoxyborohydride, at a temperature of about 0° C to about 50 °C, typically at ambient temperature for about one hour to about 24 hours.
  • a reducing agent preferably sodium triacetoxyborohydride
  • a base may be added to facilitate the reaction, preferably an amine base such as diisopropylethylamine.
  • the same Formula l(c) compounds can be prepared by reacting a Formula l(b) compound with an alkylating agent, such as an aryl alkyi halide or an aryl alkyi mesylate and the like.
  • an alkylating agent such as an aryl alkyi halide or an aryl alkyi mesylate and the like.
  • the Formula l(b) compound is reacted with an alkylating agent in the presence of a base, preferably an amine base such as triethylamine or diisopropylethylamine, in a solvent such as 1 -propanol, A/,/V-dimethylformamide, MeCN, or THF at a temperature of ambient temperature to 100 °C, preferably at about 75 °C for about 1 hour to about 24 hours.
  • the dichloropyrimidines of Formula II wherein R is defined above can be prepared according to Scheme 2 starting from the requisite amidines VI or esters VII.
  • Formula VI amidines can be prepared by numerous methods known to those skilled in the art. For example, the corresponding nitrile can be converted first to the imidate by the treatment of the nitrile with anhydrous hydrochloric acid in ethanol at ambient temperature for 24 hours, followed by the addition of anhydrous ammonia in ethanol at ambient temperature for 24 hours to provide amidines VI.
  • dihydroxypyrimidines of formula VIII Treatment of amidines VI with dimethylmalonate or diethylmalonate under basic conditions, preferably using an alkoxide base such as sodium methoxide, in alcohol solvent, preferably methanol, at ambient temperature for about 12 hours to about 48 hours, can provide dihydroxypyrimidines of formula VIII.
  • dihydroxypyrimidines VIII can be formed by reaction of esters VII with malonamide. Addition of esters VII to a mixture of malonamide and an alkoxide base such as n-butoxide, formed by treatment of n-butanol with sodium hydride, in solvents such as toluene at temperatures around 0 °C, followed by warming to about 40 °C and overnight stirring, can provide dihydroxypyrimidines of Formula VIII.
  • the pyrimidines of Formula VIII can be nitrated to provide nitropyrimidines of Formula
  • Formula VIII compounds are added in portions to a mixture of nitric acid and acetic acid at a temperature of between 20 °C to 30 °C for about 30 minutes to about 4 hours.
  • Formula VIII diols can be dissolved in TFA at ambient temperatures and then fuming nitric acid can be added dropwise, maintaining a temperature below 25 °C followed by overnight stirring to yield nitro compounds IX.
  • the Formula X compounds wherein R is defined above can be prepared from the corresponding Formula IX compounds by reaction with a chlorinating agent.
  • the chlorinating agent is phosphorus oxychloride.
  • the Formula IX compounds can be added to phosphorus oxychloride in the presence of an amine base, preferably an aniline base such as dimethylaniline.
  • an amine base preferably an aniline base such as dimethylaniline.
  • the mixture is heated at a temperature of about 50 °C to about 105 °C, for about one hour to about 6 hours to provide the desired dichloropyrimidines X.
  • a mixture of the Formula IX compounds in phosphorous oxychloride is stirred at ambient temperature and phosphoric acid is added followed by dropwise addition of an amine base such as diisopropylethylamine while maintaining the temperature below 40 °C.
  • an amine base such as diisopropylethylamine
  • the dichloroaminopyrimidines of Formula II can be prepared from the corresponding nitro compounds of formula X by reduction of the nitro group.
  • the reduction is generally carried out by the addition of a transition metal powder, such as iron or tin, to a solution of the Formula X compound in acidic solvent such as acetic acid or aqueous hydrochloric acid.
  • the reduction is performed at a temperature of about ambient temperature to about 75 °C, preferably about 50 °C, for about 2 to 10 hours.
  • the racemic amine of Formula lll(a) where R 4 equals hydrogen can be prepared as reported by S. Kato ef a/., J. Med. C em., 1990, 33, 1406-1413. It is most conveniently prepared from the corresponding Formula XIII nitrile through a reduction reaction.
  • the reduction can be achieved by a variety of reducing agents known to those skilled in the art for reducing nitriles selectively in the presence of /V-benzyl groups. These reducing agents include but are not limited to Raney nickel, lithium aluminum hydride, or Vitride®.
  • the nitrile of Formula XIII where R 4 equals hydrogen can be prepared in one step from 2-chloroacrylonitrile (XI) and 2- benzylaminoethanol XII as described by M. J. Cases-Thomas ef a/., Bioorganic Med. Chem. Lett. 2006, 16, 2022-2025 and F. D. King et ai , J. Med. Chem., 1993, 36, 683-689.
  • the chiral resolution of amine lll(a) where R 4 equals hydrogen can be accomplished as described by N. Sakurai et ai , Bioorganic Med. Chem. Lett., 1998, 8, 2185-2190.
  • reaction conditions length of reaction and temperature
  • reaction conditions may vary. In general, reactions were followed by thin layer chromatography or mass spectrometry, and subjected to work-up when appropriate.
  • Purifications may vary between experiments: in general, solvents and the solvent ratios used for eluants/gradients were chosen to provide appropriate R f s or retention times.
  • Cyclopropylcarboxamidine hydrochloride (1) A solution of cyclopropanecarbonitrile (70 g, 1 .04 mol) in ethanol (50 mL) was added to a saturated solution of dry HCI gas in dry ethanol (93 g) along with slight cooling. The resulting mixture was then stirred at RT for 24 h. The thick suspension formed was diluted with ethanol (25 mL) and cooled with an ice-water bath. An ethanolic ammonia solution (103.2 g) was added slowly to the ethanol mixture over ⁇ 30 min. The cooling bath was then removed, and the mixture was stirred at 23 °C for another 24 h.
  • Examples 2-4 were prepared following the procedure for the preparation of (R)-3-((4- benzylmorpholin-2-yl)methyl)-5-cyclopropyl-3/-/-[1 ,2,3]triazolo[4,5-c/]pyrimidin-7-amine (9) in Example 1 but using the appropriate starting materials: 4,6-dichloro-2-cyclopropylpyrimidin-5- amine (5) or 4,6-dichloro-2-methylpyrimidin-5-amine (10), commercially available from Sigma- Aldrich Chemical Company, St. Louis, Mo., and 1 -[4-benzylmorpholin-2-yl]methanamine (6), (6- S), or (6-R).
  • dichloronitropyrimidine 17 (21 .6 g, 82.4 mmol) in AcOH (344 mL) was added iron powder (21.6 g, 388 mmol) portion-wise.
  • the mixture was SLOWLY heated to 50 °C for 75 min and formed a very thick gray/brown sludge. After cooling to RT, the mixture was diluted with ethyl acetate, filtered through Celite and concentrated. The resulting material was dissolved in ethyl acetate, washed with water (3x), brine (2x), dried over MgS0 4 , filtered and concentrated to provide 17.1 g of 18 as a light brown solid.
  • LCMS m/z 230.0 (M+1 ). 9 F NMR (376 MHz, DMSO-d 6 ) ⁇ -67.82 (s, 3 F).
  • Benzyl morpholine 21 (16.6 g, 42.2 mmol) was dissolved in MeTHF (166 imL) in a hydrogenation vessel, charged with 10 % Pd(OH) 2 on carbon (1.66 g, 10 % w/w catalyst load), and placed under a hydrogen atmosphere (50 psi). The reaction mixture was heated to 55 0 C overnight. The catalyst was removed by filtration. The filtrate was concentrated to afford12.7 g of 23 as a light-colored solid.
  • Morpholine 29 (5.58 g, 22.38 mmol) was dissolved in water (0.4 mL), acetic acid (5.4 mL), and formaldehyde (2.55 mL of a 37% aqueous solution).
  • Zinc dust (2.99 g, 44.8 mmol) was added and the mixture was heated at 60 °C for 1 h, then cooled, filtered to remove the zinc, and rinsed with water.
  • Aqueous ammonia was added to the filtrate. Upon standing approximately 10 min, a white solid began to form in the flask. A stirbar was added and the mixture was stirred an additional 30 min. The resulting slurry was cooled in an ice/water bath for 30 min and then filtered to collect the solid.
  • Triethylamine 80 uL, 0.57 mmol was added to a solution of morpholine 27 (40 mg, 0.11 mmol) and 2-picolyl chloride hydrochloride (28.3 mg, 0.172 mmol) in 1-propanol (3 mL). The mixture was heated at 75 °C for 18 h. The mixture was cooled, diluted with saturated aqueous sodium bicarbonate solution and extracted with EtOAc (2x). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated.
  • Examples 17-21 are shown in Table 3 and were prepared according to the procedure described in Example 16 using the corresponding morpholine starting materials (23, 27, 28, or 30) and the requisite alkyl halide.
  • Triethylamine (352 ⁇ , 2.52 mmol) was added to a solution of morpholine 26 (139 mg,
  • Examples 23-25 are shown in Table 4 and were prepared according to the procedure described in Example 22 using the corresponding morpholine starting materials (27, 28, or 30) and the requisite heteroaryl halides.
  • Examples 27-58 are shown in Table 5 and were prepared according to the procedure described in Example 26 using the corresponding morpholine starting materials (26, 27, 28, or 30) and the requisite aldehydes.
  • Nitrile 80 (10 g, 49.44 mmol) was combined with concentrated HCI (50 imL) at RT in a sealed glass bottle with magnetic stirbar. The mixture was heated to 90 °C for 16 h and then cooled to RT. A precipitate formed and the slurry was concentrated and then azeotroped from toluene to provide 15.0 g of 81 as a light pink solid.
  • the diastereomers were separated by chiral HPLC using the following conditions: a Chiracel OJ-H column (250 mm x 21.0 mm), flow rate of 65 mL/min, and 10% ethanol in carbon dioxide.
  • the 4 diastereomers were separated but diastereomer 78 was contaminated with an impurity and required a second chiral chromatography using a ChiralPAK AD-H column (250 mm x 21 mm), a flow rate of 65 mL/min and 15% isopropanol in carbon dioxide.
  • the diastereomers are listed below in order of elution with the diastereomer with the shortest retention time listed first.
  • Diastereomer 76 LCMS m/z 408.3 (M+1). H NMR (400 MHz, CDCI 3 ) ⁇ 7.18-7.26 (m,
  • Diastereomer 78 LCMS m/z 408.3 (M+1). H NMR (400 MHz, CDCI 3 ) ⁇ 7.28-7.37 (m,
  • Morpholine 85 (135 mg, 0.42 mmol) was dissolved in water (2 imL) and acetic acid (0.1 imL, 1 .7 mmol). Formaldehyde solution (0.05 imL of a 37% aqueous solution) was added followed by zinc dust (56 mg, 0.85 mmol). The reaction mixture was heated at 60 °C overnight and then ammonium hydroxide (3 imL of 30 % aqueous solution) was added.
  • PDE8A SPA assay protocol Test compounds were solubilized in 100% dimethyl sulfoxide and diluted to the required concentrations in 15% dimethyl sulfoxide/water. The human PDE8A enzyme was thawed slowly and diluted in 50 imM Tris HCI buffer (pH 7.5 at RT) containing 1 .3 imM MgCI 2 . Incubations were initiated by the addition of enzyme solution to 384- well plates containing test drugs and radioligand (20 nM 3 H-cAMP). After a 30 min. incubation at RT, phosphodiesterase SPA beads (Amersham/GE) were then added to the assay plate at a concentration of 0.2 mg/well to stop the reaction.
  • test compounds were assessed by measuring the amount of 3 H-5'AMP resulting from enzyme cleavage of 3 H-cAMP radioligand.
  • Levels of 3 H-5'AMP bound to SPA beads were determined by paralux counting of the assay plates in a Microbeta Trilux Counter (PerkinElmer). Non-specific binding was determined by radioligand binding in the presence of a saturating concentration (10 ⁇ ) of a potent PDE8 inhibitor.
  • PDE8B SPA assay protocol Same as the PDE8A SPA assay protocol except that human PDE8B enzyme was used instead of the human PDE8A enzyme.
  • PDE8B fluorescence polarization (FP) assay protocol Test compounds were solubilized in 100% dimethyl sulfoxide and diluted to the required concentrations in 20% DMSO/assay buffer. The human PDE8B enzyme was thawed and diluted in assay buffer: 10 mM Tris HCI (pH 8.0 at RT), 10 mM Tris HCI (pH 7.0 at RT), 10 mM MgCI 2 and 0.007% Tween- 20. Enzyme and test compounds were added to a 384-well plate, followed by the TAMARA- cAMP substrate (Molecular Devices R7457) to initiate the reaction. After a 45 min.
  • TAMARA- cAMP substrate Molecular Devices R7457
  • binding reagent (Molecular Devices Original Binding System R8073) was added to the assay and allowed to incubate another 60 min. Plates were read on the Analyst GT. Activity of test compounds was assessed by calculating % inhibition, using total counts and background to determine the assay window.
  • IC 50 value concentration at which 50% inhibition of specific binding occurs

Abstract

L'invention concerne des composés de formule (I) : où R1, R2, R3, R4 et R5 sont tels que définis présentement.
PCT/IB2010/054953 2009-11-16 2010-11-02 Triazolopyrimidines substituées comme inhibiteurs de pde8 WO2011058478A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26142809P 2009-11-16 2009-11-16
US61/261,428 2009-11-16

Publications (1)

Publication Number Publication Date
WO2011058478A1 true WO2011058478A1 (fr) 2011-05-19

Family

ID=43413841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/054953 WO2011058478A1 (fr) 2009-11-16 2010-11-02 Triazolopyrimidines substituées comme inhibiteurs de pde8

Country Status (1)

Country Link
WO (1) WO2011058478A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103221413A (zh) * 2011-08-12 2013-07-24 上海恒瑞医药有限公司 ***并嘧啶类衍生物、其制备方法及其用途
JP2015535242A (ja) * 2013-09-30 2015-12-10 コリア リサーチ インスティテュート オブ ケミカル テクノロジー 新規なトリアゾロピラジン誘導体及びその用途
US9505728B2 (en) 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof
US9676754B2 (en) 2012-12-20 2017-06-13 Inception 2, Inc. Triazolone compounds and uses thereof
US9776976B2 (en) 2013-09-06 2017-10-03 Inception 2, Inc. Triazolone compounds and uses thereof
ES2696516A1 (es) * 2017-07-12 2019-01-16 Consejo Superior Investigacion Compuestos derivados de piperidina como inhibidores de PDE8A
CN112266386A (zh) * 2020-10-20 2021-01-26 中山大学 一种2-氯腺嘌呤衍生物、制备方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090239884A1 (en) * 2006-04-27 2009-09-24 Paul Epstein Methods of Treating Inflammation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090239884A1 (en) * 2006-04-27 2009-09-24 Paul Epstein Methods of Treating Inflammation

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
"Bioreversible Carriers in Drug Design", 1987, PERGAMON PRESS
"COMPENDIUM OF ORGANIC SYNTHETIC METHODS", vol. I-XII, WILEY-INTERSCIENCE
"Handbook of Pharmaceutical Excipients", 1999, AMERICAN PHARMACEUTICAL ASSOCIATION
"Pharmaceutical Dosage Forms", 1980, MARCEL DECKER
A. F. ABDEL-MAGID ET AL., J. ORG. CHEM., vol. 61, 1996, pages 3849 - 3862
BIOORGANIC MED. CHEM. LETT., vol. 16, 2006, pages 2022 - 2025
BIOORGANIC MED. CHEM. LETT., vol. 8, 1998, pages 2185 - 2190
F. D. KING ET AL., J. MED. CHEM., vol. 36, 1993, pages 683 - 689
FINNIN; MORGAN, J. PHARM. SCI., vol. 88, 1999, pages 955 - 958
H. BUNDGAARD: "Design of Prodrugs", 1985, ELSEVIER
HOOVER, JOHN E.: "Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING CO.
J. MED. CHEM., vol. 36, 1993, pages 683 - 689
M. J. CASES-THOMAS ET AL., BIOORGANIC MED. CHEM. LETT., vol. 16, 2006, pages 2022 - 2025
S. KATO ET AL., J. MED. CHEM., vol. 33, 1990, pages 1406 - 1413
SAKURAI ET AL., BIOORGANIC MED. CHEM. LETT., vol. 8, 1998, pages 2185 - 2190
T. HIGUCHI; W. STELLA: "Novel Delivery Systems", vol. 14, 1975, ACS SYMPOSIUM SERIES
T. W. GREENE: "Protective Groups in Organic Chemistry", 1981, JOHN WILEY & SONS
T. W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Chemistry", 1991, JOHN WILEY & SONS
T. W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Chemistry", 1999, JOHN WILEY & SONS
WANG ET AL., BIOCHEMISTRY, vol. 47, no. 48, 2008, pages 12760 - 8

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103221413A (zh) * 2011-08-12 2013-07-24 上海恒瑞医药有限公司 ***并嘧啶类衍生物、其制备方法及其用途
CN103221413B (zh) * 2011-08-12 2016-01-20 上海恒瑞医药有限公司 ***并嘧啶类衍生物、其制备方法及其用途
US9505728B2 (en) 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof
US9676754B2 (en) 2012-12-20 2017-06-13 Inception 2, Inc. Triazolone compounds and uses thereof
US10568871B2 (en) 2012-12-20 2020-02-25 Tempest Therapeutics, Inc. Triazolone compounds and uses thereof
US11666557B2 (en) 2012-12-20 2023-06-06 Tempest Therapeutics, Inc. Triazolone compounds and uses thereof
US9776976B2 (en) 2013-09-06 2017-10-03 Inception 2, Inc. Triazolone compounds and uses thereof
JP2015535242A (ja) * 2013-09-30 2015-12-10 コリア リサーチ インスティテュート オブ ケミカル テクノロジー 新規なトリアゾロピラジン誘導体及びその用途
ES2696516A1 (es) * 2017-07-12 2019-01-16 Consejo Superior Investigacion Compuestos derivados de piperidina como inhibidores de PDE8A
WO2019012173A1 (fr) * 2017-07-12 2019-01-17 Consejo Superior De Investigaciones Científicas Composés dérivés de pipéridine utilisés en tant qu'inhibiteurs de pde8a
CN112266386A (zh) * 2020-10-20 2021-01-26 中山大学 一种2-氯腺嘌呤衍生物、制备方法及应用
CN112266386B (zh) * 2020-10-20 2022-03-25 中山大学 一种2-氯腺嘌呤衍生物、制备方法及应用

Similar Documents

Publication Publication Date Title
KR101421852B1 (ko) 카세인 키나제 억제제로서의 이미다졸 유도체
US8183238B2 (en) Bicyclic and tricyclic compounds as KAT II inhibitors
US20090291938A1 (en) Polo-like kinase inhibitors
US20110224231A1 (en) Novel Lactams as Beta Secretase Inhibitors
WO2011058478A1 (fr) Triazolopyrimidines substituées comme inhibiteurs de pde8
JP2010536869A (ja) ナフチルピリミジン、ナフチルピラジンおよびナフチルピリダジン類似体、ならびにＷｎｔ−βカテニン細胞メッセージ伝達系のアゴニストとしてのその使用
US8933095B2 (en) KAT II inhibitors
JP2017527606A (ja) 三環系誘導体
CA2603876A1 (fr) Antagonistes de nmda/nr2b a base de n-alkyl-azacycloalkyle
US20120202787A1 (en) Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators
KR20110000749A (ko) 신경변성 질환의 치료용 스피로 피페리딘류
CA3179059A1 (fr) Inhibiteurs de traduction du collagene 1 et leurs procedes d'utilisation
AU679102B2 (en) Antiallergic imidazoazepines
EP2556076A2 (fr) Nouveaux composés sultame
CN116322692A (zh) 自分泌运动因子抑制剂化合物
EP3028703A1 (fr) INHIBITEUR DE LA VOIE DE SIGNALISATION Wnt

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10781742

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10781742

Country of ref document: EP

Kind code of ref document: A1